Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic equivalence of vildagliptin 100 mg once daily modified release to 50 mg twice daily immediate release formulation: An open-label, randomized, two-period, single- and multiple-dose, 6-day crossover study.
Sangana R, Mittal H, Barsainya S, Hoermann A, Borde P, Naik S, Thorat AV, Zhang J, Valentin MA, Kalluri S. Sangana R, et al. Among authors: valentin ma. Diabetes Metab Syndr. 2022 Mar;16(3):102438. doi: 10.1016/j.dsx.2022.102438. Epub 2022 Feb 25. Diabetes Metab Syndr. 2022. PMID: 35272176 Clinical Trial.
¹⁸F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: a prospective, randomized, controlled clinical study.
Frost ML, Moore AE, Siddique M, Blake GM, Laurent D, Borah B, Schramm U, Valentin MA, Pellas TC, Marsden PK, Schleyer PJ, Fogelman I. Frost ML, et al. Among authors: valentin ma. J Bone Miner Res. 2013 Jun;28(6):1337-47. doi: 10.1002/jbmr.1862. J Bone Miner Res. 2013. PMID: 23322666 Free article. Clinical Trial.
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, McCann L, Ozdogan H, Rutkowska-Sak L, Schneider R, Gerloni V, Harel L, Terreri M, Houghton K, Joos R, Kingsbury D, Lopez-Benitez JM, Bek S, Schumacher M, Valentin MA, Gram H, Abrams K, Martini A, Lovell DJ, Nirmala NR, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Brachat AH, et al. Among authors: valentin ma. Arthritis Res Ther. 2017 Jan 23;19(1):13. doi: 10.1186/s13075-016-1212-x. Arthritis Res Ther. 2017. PMID: 28115015 Free PMC article. Clinical Trial.
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ. Dörner T, et al. Among authors: valentin ma. Ann Rheum Dis. 2019 May;78(5):641-647. doi: 10.1136/annrheumdis-2018-214720. Epub 2019 Mar 2. Ann Rheum Dis. 2019. PMID: 30826774 Clinical Trial.
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD. Kolbinger F, et al. Among authors: valentin ma. J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8. doi: 10.1016/j.jaci.2016.06.038. Epub 2016 Aug 5. J Allergy Clin Immunol. 2017. PMID: 27502297 Free article.
31 results